Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank Anne Aarnio for excellent technical assistance and the DNA Sequencing and Genomics Laboratory at the Institute of Biotechnology, University of Helsinki for the NanoString analyzes.

Disclosure statement

LK has received consulting, advisory or speakers’ bureau honoraria from Roche and Amgen, Bristol-Myers Squibb, and Roche. SL has received consulting, advisory or speakers’ bureau honoraria from Gilead, Incyte, Novartis, Orion, Roche and Sofi. MH has received consulting, speakers’ bureau, or advisory honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Novartis, Roche, and MedEngine. SM has received consulting or advisory honoraria from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Astra Zeneca, Servier, Pierre Fabre, and Sanofi; speakers’ bureau honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, and Sanofi. All remaining authors have declared no conflicts of interest.

Data availability statement

The data supporting the findings of this study are available from the corresponding author, upon reasonable request.

Additional information

Funding

This study has been supported by Finnish Melanoma Group (LK), Helsinki University Hospital Cancer Center (MH), Finnish Cancer Societies (SL) and Academy of Finland (SL).